From Rik. Enjoy!
Sam,
The OTC Market representatives seem incredibly arbitrary in all of their
reviews. Even if their current reasoning would be the contested SEC matter -
- -that makes absolutely no sense. The lawsuit is over three years old. Why
were we not a risk to investors when we had the lawsuit AND we were
delinquent in our filings; and now we are considered a risk to investors
with a 3-year old lawsuit and fully current in our reporting requirements.
This is nothing more than a contested civil lawsuit and certainly does not
raise to the level of a risk to investors. Especially because the lawsuit is
fully disclosed and reserved in our financials.
In the meantime, the company is doing very well. We've recertified our clean
room, increased manufacturing capacity, brought in raw materials for new
production of Nyloxin and Pet Pain-Away. We're working on expanding the Pet
Pain-Away line and are running a full page ad in the December issue of Pet
Business magazine.
The only outstanding issues for the company are the SEC lawsuit and the CE
designation. We continue to fight the SEC suit and believe it to lack merit.
Remember that we've already received a partial dismissal in this case -
which is amazing as most judges will NEVER dismiss a case from a government
regulator. We expect a positive outcome for the company either in a
settlement or a vindication in trial.
The CE designation has damaged the company, harmed our reputation and
reduced our market value dramatically. We've tried to play nice, but this
has gone on for far too long; this is now in the hands of our attorneys.
Once we have something to report, we will keep everyone posted.
Have a Happy Thanksgiving,
Rik
